Skip to main content

Publications

featured publications

  • CRISPitope: A generic platform to model target antigens for adoptive T cell transfer therapy in mouse tumor models.

    STAR protocols

    Authors: Maike Effern, Nicole Glodde, Emma Bawden, Jana Liebing, Daniel Hinze, Thomas Tüting, Thomas Gebhardt, Michael Hölzel

  • Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma.

    Journal of neuro-oncology

    Authors: Johannes Wach, Ági Güresir, Valeri Borger, Patrick Schuss, Albert Becker, Christoph Coch, Marie-Therese Schmitz, Michael Hölzel, Marieta Toma, Ulrich Herrlinger, Hartmut Vatter, Erdem Güresir

  • C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.

    Clinical & translational immunology

    Authors: Niklas Klümper, Philipp Schmucker, Oliver Hahn, Benedikt Höh, Angelika Mattigk, Severine Banek, Jörg Ellinger, Julia Heinzelbecker, Danijel Sikic, Markus Eckstein, Arne Strauß, Friedemann Zengerling, Michael Hölzel, Philip Zeuschner, Charis Kalogirou

  • A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment.

    Signal transduction and targeted therapy

    Authors: Susanna S Ng, Sonia Leonardelli, Michael Hölzel

  • Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?

    Journal of clinical medicine

    Authors: Barbara Link, Adriana Torres Crigna, Michael Hölzel, Frank A Giordano, Olga Golubnitschaja

  • Combining FORGE Score and Histopathological Diagnostic Criteria of Atypical Meningioma Enables Risk Stratification of Tumor Progression.

    Diagnostics (Basel, Switzerland)

    Authors: Johannes Wach, Tim Lampmann, Ági Güresir, Hartmut Vatter, Albert J Becker, Michael Hölzel, Marieta Toma, Erdem Güresir

  • Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.

    Journal of immunotherapy (Hagerstown, Md. : 1997)

    Authors: Damian J Ralser, Niklas Klümper, Heidrun Gevensleben, Romina Zarbl, Christina Kaiser, Jennifer Landsberg, Michael Hölzel, Sebastian Strieth, Andree Faridi, Alina Abramian, Dimo Dietrich

  • promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.

    Journal for immunotherapy of cancer

    Authors: Niklas Klümper, Damian J Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michèle J Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan, Julie Steinestel, Konrad Steinestel, Ralph M Wirtz, Danijel Sikic, Markus Eckstein, Glen Kristiansen, Marieta Toma, Michael Hölzel, Manuel Ritter, Sebastian Strieth, Jörg Ellinger, Dimo Dietrich

  • FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in Intracranial Meningiomas.

    Cancers

    Authors: Johannes Wach, Tim Lampmann, Ági Güresir, Patrick Schuss, Hartmut Vatter, Ulrich Herrlinger, Albert Becker, Michael Hölzel, Marieta Toma, Erdem Güresir

  • Top publication

    LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding.

    Nature biotechnology

    Authors: Kerstin U Ludwig, Ricarda M Schmithausen, David Li, Max L Jacobs, Ronja Hollstein, Katja Blumenstock, Jana Liebing, Mikołaj Słabicki, Amir Ben-Shmuel, Ofir Israeli, Shay Weiss, Thomas S Ebert, Nir Paran, Wibke Rüdiger, Gero Wilbring, David Feldman, Bärbel Lippke, Nina Ishorst, Lara M Hochfeld, Eva C Beins, Ines H Kaltheuner, Maximilian Schmitz, Aliona Wöhler, Manuel Döhla, Esther Sib, Marius Jentzsch, Eva-Maria C Moench, Jacob D Borrajo, Jonathan Strecker, Julia Reinhardt, Brian Cleary, Matthias Geyer, Michael Hölzel, Rhiannon Macrae, Markus M Nöthen, Per Hoffmann, Martin Exner, Aviv Regev, Feng Zhang, Jonathan L Schmid-Burgk